UnknownPhase 2

T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant

United Kingdom78 participantsStarted 2009-09

Plain-language summary

RATIONALE: An infusion of cytomegalovirus-specific T lymphocytes may prevent or reduce cytomegalovirus infection during the first year after a donor stem cell transplant. PURPOSE: This randomized phase II trial is studying T-lymphocyte infusion to see how well it works compared with standard therapy in treating patients at risk of cytomegalovirus infection after a donor stem cell transplant.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Planning allogeneic peripheral blood stem cell transplantation (PBSCT) using a conditioning regimen containing alemtuzumab and radiotherapy * Sibling or matched unrelated donor available * Patients and donor matched for ≥ one of the following HLA alleles: * HLA-A\*0101 * HLA\*0201 * HLA-A\*1101 * HLA-A\*2402 * HLA-B\*0702 * HLA-B\*0801 * HLA-B\*3502 * No donors whose stem cells have already been collected and cryopreserved prior to transplant * Patient and donor must be CMV seropositive * Stem cell harvests ≥ 4.0 x 10\^6 CD34 cells/kg PATIENT CHARACTERISTICS: * See Disease Characteristics PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior bone marrow transplantation * No concurrent participation in another therapeutic transplantation study

What they're measuring

CMV reactivation in the first year after ASCT measured by quantitative PCR

Trial details

NCT IDNCT00986557

SponsorUniversity Hospital Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-08

View on ClinicalTrials.gov More Graft Versus Host Disease trials